JelikaLite has completed a Phase I placebo-controlled clinical trial of its prototype, showing statistically significant improvement in children who received the treatment. The company has also received a Breakthrough Device Designation from the FDA for its Cognilum system.
Organizations Involved
None
Founders
Eugenia Steingold, Katya Sverdlov, Luis DeTaboada
Company Description
JelikaLite is focused on developing Cognilum, a medical solution aimed at reducing autism symptoms in children through noninvasive brain stimulation using near-infrared light, EEG sensors, and an AI personalization platform. The company aims to provide a personalized, home-based treatment option for children with autism, addressing the limitations of current therapies and medications.